慢性搔痒症市场－全球及区域分析：按国家/地区划分－分析与预测（2025-2035）

全球慢性搔痒症市场分析与预测（2025-2035）

慢性搔痒是指持续超过六週的持续性、通常较为严重的搔痒。

慢性搔痒可能是多种潜在疾病的症状，包括湿疹、干癣、肝病、肾臟病和神经系统疾病。慢性搔痒不只是令人烦恼，它还会严重影响患者的生活质量，导致睡眠障碍、焦虑甚至忧郁症。与外部因素（例如昆虫叮咬）引起的暂时性搔痒不同，慢性搔痒通常与内部因素有关，因此更难治疗。它还可能伴随其他症状，例如患处发红、肿胀和疤痕。

慢性搔痒症市场的发展主要受皮肤病和慢性疾病盛行率上升、公众意识提高、诊断水平提高以及标靶治疗进步的推动。慢性搔痒症通常是湿疹、干癣、肝病和慢性肾臟病等潜在疾病的症状。随着全球人口老化和这些疾病盛行率的增加，对有效治疗方法的需求也随之增长。例如，根据美国皮肤病学会统计，光在美国就有超过3,160万人患有湿疹。这些人口结构的变化正在推动人们对缓解这些疾病引起的搔痒和不适症状的治疗方法的需求。

此外，慢性搔痒日益被认为是重要的临床问题。医疗专业人员对慢性搔痒与多种疾病的关联有了更深入的了解，患者也越来越倾向于寻求医疗帮助，尤其是那些因持续性搔痒而影响生活品质的患者。诊断技术的进步和患者意识提升的提高也促进了对搔痒治疗需求的成长。

儘管目前有多种治疗方法可以治疗慢性搔痒，但经美国食品药物管理局 (FDA)核准的针对搔痒的标靶治疗数量仍然有限，这限制了患者的治疗选择。儘管研究取得了进展，但美国皮质类食品药物管理局和抗组织胺等治疗方法仍然被广泛使用，然而这些方法往往无法解决搔痒的根本原因，因此在长期治疗中效果有限。

此外，许多现有的治疗慢性搔痒的药物，例如皮质类固醇和抗组织胺药，都伴随皮肤变薄、嗜睡和感染疾病风险增加等副作用，这些副作用会影响患者对治疗方案的依从性。长期使用全身性药物可能导致併发症，尤其是在老年患者中，这会妨碍患者完全坚持治疗方案。慢性搔痒也常被漏诊或误诊，因为它常被归因于其他皮肤疾病或仅被视为一种症状。这可能导致患者直到症状恶化才寻求治疗或接受适当的护理，从而限制了有效治疗方法的市场潜力。

生物製药疗法在治疗慢性搔痒方面越来越受欢迎，尤其是在湿疹、干癣和其他皮肤病患者中。此外，人们越来越关注针对搔痒特定分子机制的标靶药物的研发。与传统的全身性治疗相比，这些治疗方法有望在副作用最小的情况下提供长期的症状缓解。

此外，随着我们对搔痒分子路径的了解不断深入，市场正朝着基于搔痒具体病因的精准医疗方向发展。这种方法能够透过针对潜在病因（例如湿疹或肝病）而非仅仅掩盖症状，来有效控制慢性搔痒。

市场上的竞争策略包括扩大现有药物的适应症、引入新的生物製药以及改进局部治疗的配方。

本报告对全球慢性搔痒症市场进行了分析，概述了市场情况，并介绍了区域趋势和参与该市场的公司的概况。

目录

执行摘要

第一章 全球慢性搔痒症市场：产业展望

• 市场概览
• 流行病学分析
• 监管状态
• 主要趋势
• 临床试验分析
• 市场动态
  • 影响分析
  • 市场驱动因素
  • 市场约束
  • 市场机会

2. 全球慢性搔痒症市场（按地区划分，单位：百万美元，2023-2035年）

• 北美洲
  • 市场动态
  • 市场规模及预测
• 欧洲
  • 市场动态
  • 市场规模及预测
• 亚太地区
  • 市场动态
  • 市场规模及预测

3. 慢性搔痒症市场：竞争格局与公司概况

• 竞争格局
  • 关键策略和发展（按公司划分）
• 公司简介
  • Nuogen Pharma
  • Sanofi
  • GalaxoSmithKline plc
  • Chugai Pharmaceutical
  • Galderma
  • Mirum Pharmaceuticals
  • 其他的

第四章调查方法

Global Chronic Pruritus Market, Analysis and Forecast: 2025-2035

Chronic pruritus is a persistent and often severe form of itching that lasts for more than six weeks. It can be a symptom of various underlying medical conditions, including eczema, psoriasis, liver disease, kidney disease, and neurological disorders. Chronic pruritus is more than just an irritation; it can significantly affect a person's quality of life, leading to sleep disturbances, anxiety, and even depression. Unlike temporary itching caused by external factors (like an insect bite), chronic pruritus is often associated with internal causes, making it more challenging to treat. It can occur alongside other symptoms such as redness, swelling, or scarring in the affected areas.

The chronic pruritus market is driven by increasing prevalence of skin disorders and chronic conditions, increasing awareness and diagnosis, and advancement in targeted therapies. Chronic pruritus is often a symptom of underlying conditions like eczema, psoriasis, liver diseases, and chronic kidney disease. As the global population ages and the prevalence of these conditions increases, the demand for effective treatments for chronic pruritus has also grown. For instance, eczema affects more than 31.6 million people in the U.S. alone, according to the American Academy of Dermatology. This demographic shift is driving demand for therapies to manage itching and discomfort associated with these conditions.

Moreover, there is a growing recognition of chronic pruritus as a significant clinical issue. Healthcare professionals are more attuned to its link to various diseases, and patients are increasingly seeking medical attention for persistent itching, especially when it affects quality of life. Advances in diagnostic techniques and greater patient awareness contribute to the rising demand for pruritus treatments.

Although there are multiple treatments available for managing chronic pruritus, the FDA has yet to approve many targeted therapies specifically for pruritus, which can limit treatment options for patients. Despite advances in research, treatments like topical corticosteroids and antihistamines are still commonly used but often fail to address the underlying causes of itching, leading to limited effectiveness for long-term management.

In addition, many of the existing treatments for chronic pruritus, such as corticosteroids and antihistamines, come with side effects like skin thinning, drowsiness, and increased risk of infection, which can impact patient adherence to treatment regimens. Long-term use of systemic medications, particularly in the elderly, can lead to complications, which may deter patients from fully complying with treatment plans. Also, chronic pruritus is often underdiagnosed or misdiagnosed, as it is frequently attributed to other dermatological conditions or simply managed as a symptom rather than a condition in its own right. This limits the market potential for effective therapies, as patients may not seek treatment or receive appropriate care until their condition worsens.

Biologic therapies are becoming increasingly popular for treating chronic pruritus, especially in patients with eczema, psoriasis, and other skin conditions. Moreover, there is a growing focus on the development of targeted drugs that address the specific molecular mechanisms of pruritus. These therapies offer potential for long-term relief with minimal side effects compared to traditional systemic treatments.

Furthermore, with a better understanding of the molecular pathways involved in pruritus, the market is seeing a shift toward precision medicine based on the specific cause of itching. This approach allows for more effective management of chronic pruritus by targeting the underlying condition, such as eczema or liver disease, rather than just masking the symptom.

Competitive strategies within the market include expanding the therapeutic indications of existing drugs, introducing new biologics, and refining formulations of topical treatments.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Chronic Pruritus Market: Industry Outlook

• 1.1 Market Overview
• 1.2 Epidemiological Analysis
• 1.3 Regulatory Landscape
• 1.4 Key Trends
• 1.5 Clinical Trial Analysis
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Restraint
  • 1.6.4 Market Opportunities

2. Global Chronic Pruritus Market, by Region, $Million, 2023-2035

• 2.1 North America
  • 2.1.1 Market Dynamics
  • 2.1.2 Market Sizing and Forecast
    • 2.1.2.1 North America Chronic Pruritus Market, by Country
      • 2.1.2.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Market Dynamics
  • 2.2.2 Market Sizing and Forecast
    • 2.2.2.1 Europe Chronic Pruritus Market, by Country
      • 2.2.2.1.1 Germany
      • 2.2.2.1.2 U.K.
      • 2.2.2.1.3 France
      • 2.2.2.1.4 Italy
      • 2.2.2.1.5 Spain
• 2.3 Asia-Pacific
  • 2.3.1 Market Dynamics
  • 2.3.2 Market Sizing and Forecast
    • 2.3.2.1 Asia-Pacific Chronic Pruritus Market, by Country
      • 2.3.2.1.1 Japan

3. Chronic Pruritus Market: Competitive Landscape and Company Profiles

• 3.1 Competitive Landscape
  • 3.1.1 Key Strategies and Developments, by Company
    • 3.1.1.1 Funding Activities
    • 3.1.1.2 Mergers and Acquisitions
    • 3.1.1.3 Regulatory Approvals
    • 3.1.1.4 Partnerships, Collaborations, and Business Expansions
• 3.2 Company Profiles
  • 3.2.1 Nuogen Pharma
    • 3.2.1.1 Overview
    • 3.2.1.2 Top Products / Product Portfolio
    • 3.2.1.3 Top Competitors
    • 3.2.1.4 Target Customers/End-Users
    • 3.2.1.5 Key Personnel
    • 3.2.1.6 Analyst View
  • 3.2.2 Sanofi
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products / Product Portfolio
    • 3.2.2.3 Top Competitors
    • 3.2.2.4 Target Customers/End-Users
    • 3.2.2.5 Key Personnel
    • 3.2.2.6 Analyst View
  • 3.2.3 GalaxoSmithKline plc
    • 3.2.3.1 Overview
    • 3.2.3.2 Top Products / Product Portfolio
    • 3.2.3.3 Top Competitors
    • 3.2.3.4 Target Customers/End-Users
    • 3.2.3.5 Key Personnel
    • 3.2.3.6 Analyst View
  • 3.2.4 Chugai Pharmaceutical
    • 3.2.4.1 Overview
    • 3.2.4.2 Top Products / Product Portfolio
    • 3.2.4.3 Top Competitors
    • 3.2.4.4 Target Customers/End-Users
    • 3.2.4.5 Key Personnel
    • 3.2.4.6 Analyst View
  • 3.2.5 Galderma
    • 3.2.5.1 Overview
    • 3.2.5.2 Top Products / Product Portfolio
    • 3.2.5.3 Top Competitors
    • 3.2.5.4 Target Customers/End-Users
    • 3.2.5.5 Key Personnel
    • 3.2.5.6 Analyst View
  • 3.2.6 Mirum Pharmaceuticals
    • 3.2.6.1 Overview
    • 3.2.6.2 Top Products / Product Portfolio
    • 3.2.6.3 Top Competitors
    • 3.2.6.4 Target Customers/End-Users
    • 3.2.6.5 Key Personnel
    • 3.2.6.6 Analyst View
  • 3.2.7 Others

4. Research Methodology

List of Figures

• Figure: Chronic Pruritus Market (by Scenario), $Million, 2024, 2030, and 2035
• Figure: Global Chronic Pruritus Market, 2024 and 2035
• Figure: Global Chronic Pruritus Market Key Trends, Impact Analysis, 2023-2035
• Figure: North America Chronic Pruritus Market, $Million, 2023-2035
• Figure: Europe Chronic Pruritus Market, $Million, 2023-2035
• Figure: Asia-Pacific Chronic Pruritus Market, $Million, 2023-2035

List of Tables

• Table: Market Snapshot
• Table: Global Chronic Pruritus Market Dynamics, Impact Analysis
• Table: Global Chronic Pruritus Market (by Region), $Million, 2023-2035